603983.SS SHH
Guangdong Marubi Biotechnology Co., Ltd.
1W: -3.7%
1M: +8.1%
3M: +12.1%
YTD: -5.9%
1Y: -23.7%
3Y: +12.3%
5Y: -38.3%
¥30.86 ($4.61)
+0.46 (+1.51%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$3.0B
+33.4% ▲
5Y CAGR: +10.5%
Gross Profit
$2.2B
+39.5% ▲
5Y CAGR: +12.2%
Operating Income
$381M
+19.3% ▲
5Y CAGR: -9.1%
Net Income
$342M
+31.7% ▲
5Y CAGR: -7.9%
EPS (Diluted)
$0.85
+30.8% ▲
5Y CAGR: -9.1%
EBITDA
$361M
+87.7% ▲
5Y CAGR: -7.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $1.7B | $1.8B | $1.7B | $2.2B | $3.0B |
| YoY Growth | -3.1% | +2.4% | -3.1% | +28.5% | +33.4% |
| Cost of Revenue | $596M | $654M | $557M | $665M | $793M |
| Gross Profit | $1.1B | $1.1B | $1.2B | $1.6B | $2.2B |
| Gross Margin | 65.9% | 63.4% | 67.8% | 70.1% | 73.3% |
| R&D Expenses | $50M | $50M | $53M | $62M | $74M |
| SG&A Expenses | $643M | $842M | $957M | $1.3B | $1.7B |
| Operating Expenses | $577M | $834M | $967M | $1.2B | $1.8B |
| Operating Income | $573M | $299M | $207M | $319M | $381M |
| Operating Margin | 32.8% | 16.7% | 12.0% | 14.3% | 12.8% |
| Interest Expense | $1M | $1M | $4M | $7M | $10M |
| Income Before Tax | $567M | $310M | $207M | $317M | $381M |
| Tax Expense | $104M | $68M | $39M | $39M | $38M |
| Net Income | $464M | $248M | $174M | $259M | $342M |
| Net Margin | 26.6% | 13.9% | 10.1% | 11.7% | 11.5% |
| EPS (Diluted) | $1.16 | $0.62 | $0.43 | $0.65 | $0.85 |
| EBITDA | $451M | $232M | $154M | $192M | $361M |
| Shares Outstanding | 401M | 401M | 401M | 399M | 402M |